Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

STEP 1:
Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

MENDELEY PAIRING EXPIRED
Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Figure 1Loading Img

Predicting the Outer Boundaries of P-glycoprotein (P-gp)-Based Drug Interactions at the Human Blood–Brain Barrier Based on Rat Studies

View Author Information
Department of Pharmaceutics, University of Washington, Seattle, Washington 98195, United States
*(J.D.U.) Phone: (206) 685-2869. Fax: (206) 543-3204. E-mail: [email protected]
Cite this: Mol. Pharmaceutics 2014, 11, 2, 436–444
Publication Date (Web):December 23, 2013
https://doi.org/10.1021/mp400396k
Copyright © 2013 American Chemical Society

    Article Views

    575

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options

    Abstract

    Abstract Image

    Using positron emission tomography (PET), 11C-verapamil as the P-gp substrate, and cyclosporine A (CsA) as the P-gp inhibitor, we showed that the magnitude of P-gp-based drug interactions at the human blood–brain barrier (BBB) is modest. However, such interactions at clinically relevant CsA blood concentrations may be greater for substrates where P-gp plays an even larger role (fractional contribution of P-gp, ft > 0.97) in preventing the CNS entry of the drug (e.g., nelfinavir). Since we have shown that the rat is an excellent predictor of the verapamil–CsA interaction at the human BBB, we determined the magnitude of drug interaction at the rat BBB between nelfinavir and CsA. Under isoflurane anesthesia, male Sprague–Dawley rats were coadministered IV infusions of nelfinavir and escalating doses of CsA to achieve pseudo steady-state plasma/blood and brain concentrations of both drugs (blood CsA ranged 0–264.9 μM, n = 3–6/group). The percent increase in the brain:blood nelfinavir concentration ratio (determined by LC/MS) was described by the Hill equation with Emax = 6481%, EC50 = 12.3 μM, and γ = 1.6. Then, using these data, as well as in vitro data in LLCPK1 cells expressing the human P-gp, we predicted that CsA (at clinically relevant blood concentration of 1.5 μM) will increase the distribution of nelfinavir into the human brain by 236%. Collectively, our data suggest that clinically significant P-gp based drug interactions at the human BBB are possible for P-gp substrates highly excluded from the brain (ft > 0.97) and should be investigated using noninvasive approaches (e.g., PET).

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Cited By

    This article is cited by 13 publications.

    1. Annika Lindqvist, Siv Jönsson, and Margareta Hammarlund-Udenaes . Exploring Factors Causing Low Brain Penetration of the Opioid Peptide DAMGO through Experimental Methods and Modeling. Molecular Pharmaceutics 2016, 13 (4) , 1258-1266. https://doi.org/10.1021/acs.molpharmaceut.5b00835
    2. Edna F. Choo, Justin Ly, Jocelyn Chan, Sheerin K. Shahidi-Latham, Kirsten Messick, Emile Plise, Cristine M. Quiason, and Lulu Yang . Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib. Molecular Pharmaceutics 2014, 11 (11) , 4199-4207. https://doi.org/10.1021/mp500435s
    3. Tingting Wang, Yingjie Guo, Yang He, Tianming Ren, Lei Yin, John Paul Fawcett, Jingkai Gu, Huimin Sun. Impact of molecular weight on the mechanism of cellular uptake of polyethylene glycols (PEGs) with particular reference to P-glycoprotein. Acta Pharmaceutica Sinica B 2020, 10 (10) , 2002-2009. https://doi.org/10.1016/j.apsb.2020.02.001
    4. Xiaomin Liang, Kelly MacLennan Staiger, Ellen Riddle, Jia Hao, Yurong Lai. Role of transporters in drug disposition and drug-drug interactions. 2020, 311-337. https://doi.org/10.1016/B978-0-12-820018-6.00010-7
    5. Donglu Zhang, Cornelis E.C.A. Hop, Gabriela Patilea-Vrana, Gautham Gampa, Herana Kamal Seneviratne, Jashvant D. Unadkat, Jane R. Kenny, Karthik Nagapudi, Li Di, Lian Zhou, Mark Zak, Matthew R. Wright, Namandjé N. Bumpus, Richard Zang, Xingrong Liu, Yurong Lai, S. Cyrus Khojasteh. Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule–Related Therapeutic Modalities. Drug Metabolism and Disposition 2019, 47 (10) , 1122-1135. https://doi.org/10.1124/dmd.119.086744
    6. Kazuya Ishida, Mohammed Ullah, Beáta Tóth, Viktoria Juhasz, Jashvant D. Unadkat. Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides. Drug Metabolism and Disposition 2018, 46 (9) , 1251-1258. https://doi.org/10.1124/dmd.118.080770
    7. Pichaya Jumnongprakhon, Sivanan Sivasinprasasn, Piyarat Govitrapong, Chainarong Tocharus, Jiraporn Tocharus. Activation of melatonin receptor (MT1/2) promotes P-gp transporter in methamphetamine-induced toxicity on primary rat brain microvascular endothelial cells. Toxicology in Vitro 2017, 41 , 42-48. https://doi.org/10.1016/j.tiv.2017.02.010
    8. Marloes J.A. Joosen, Stefanie M. Vester, Jouk Hamelink, Steven D. Klaassen, Roland M. van den Berg. Increasing nerve agent treatment efficacy by P-glycoprotein inhibition. Chemico-Biological Interactions 2016, 259 , 115-121. https://doi.org/10.1016/j.cbi.2016.06.012
    9. Li Liu, Ann C. Collier, Jeanne M. Link, Karen B. Domino, David A. Mankoff, Janet F. Eary, Charles F. Spiekerman, Peng Hsiao, Anand K. Deo, Jashvant D. Unadkat. Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study. Drug Metabolism and Disposition 2015, 43 (11) , 1795-1804. https://doi.org/10.1124/dmd.114.058685
    10. Houfu Liu, Na Yu, Sijie Lu, Sumito Ito, Xuan Zhang, Bhagwat Prasad, Enuo He, Xinyan Lu, Yang Li, Fei Wang, Han Xu, Gang An, Jashvant D. Unadkat, Hiroyuki Kusuhara, Yuichi Sugiyama, Jasminder Sahi. Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2– Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration. Drug Metabolism and Disposition 2015, 43 (7) , 1008-1018. https://doi.org/10.1124/dmd.115.064170
    11. B Prasad, JD Unadkat. The concept of fraction of drug transported (f t ) with special emphasis on BBB efflux of CNS and antiretroviral drugs. Clinical Pharmacology & Therapeutics 2015, 97 (4) , 320-323. https://doi.org/10.1002/cpt.72
    12. Bruno Stieger, Bo Gao. Drug Transporters in the Central Nervous System. Clinical Pharmacokinetics 2015, 54 (3) , 225-242. https://doi.org/10.1007/s40262-015-0241-y
    13. B Wulkersdorfer, T Wanek, M Bauer, M Zeitlinger, M Müller, O Langer. Using Positron Emission Tomography to Study Transporter-Mediated Drug–Drug Interactions in Tissues. Clinical Pharmacology & Therapeutics 2014, 96 (2) , 206-213. https://doi.org/10.1038/clpt.2014.70